5Badimon L, Vilalur G, Sanchez S, et al, Atheromatous plaque formation and thrombogenesis: formation, risk factors and therapeutic approaches[J]. Eur Heart J, 2001, 3(suppl I): I 16.
6Manoharan G, Ntalianis A, Muller O, et al. Severity of coronary arterial stenoses responsible for acute coronary syndromes[J]. Am J.Cardiol, 2009, 103(9): 1183-1188.
8Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes[J]. N Engl J Med, 2001, 345(14): 1022-1029.
9Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes-review and clinical implications[J]. ClinChem Lab Med, 2011, 49(2): 177-184.
10Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non- ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide[J]. Circulation, 2002, 105(15): 1760-1763.
9Smith S C, Feldman T E, Hirshfeld J W, et al. ACC/AHA/SCAI 2005 Guideline Update fou Percutaneous Coronary Intervention-- Summary Article: A Report of the American College of Cardiology/ american Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guide- lines for Percutaneous Coronary Intervention) [J]. J Am Coll Car- diol,2006,47(1) :216--235.
10Nallmothu B K, Bates E R. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing everything? [J]. Am J Cardiol, 2003, 92(7) :824--826.
